Methylprednisolone
ApprovedCompleted 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cluster Headache, Episodic
Conditions
Cluster Headache, Episodic, Greater Occipital Nerve Injection
Trial Timeline
Aug 1, 2019 → Aug 27, 2021
NCT ID
NCT04014634About Methylprednisolone
Methylprednisolone is a approved stage product being developed by Brain Biotech for Cluster Headache, Episodic. The current trial status is completed. This product is registered under clinical trial identifier NCT04014634. Target conditions include Cluster Headache, Episodic, Greater Occipital Nerve Injection.
What happened to similar drugs?
0 of 6 similar drugs in Cluster Headache, Episodic were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04014634 | Approved | Completed |
Competing Products
8 competing products in Cluster Headache, Episodic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab 300 mg + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| candesartan cilexetil + placebo | AstraZeneca | Phase 2 | 35 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| Bosutinib + Imatinib | Pfizer | Phase 3 | 40 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Eptinezumab | Lundbeck | Phase 3 | 37 |